Nice tight ship . I hope Layton brings the same discipline to AusCann . Waiting for the announcements on DermaCann And CPat1 , thought they might be covered in the half yearly.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%